Cancer name Acute Myeloid Leukemia
Cancer Type LAML
Immunotherapy type Oncolytic viruses;Immune Checkpoint Therapy
Treatment VSV-IFNβ-NIS
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD8+ T cells
Official Symbol Exhausted CD8+ T cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description The percentage of CD8+ cel ls in the VSV and anti-PD-L1 Ab group was 14.6%, compared to the con trol group at 2.7% and the Ab onl y group at 3.8%. CD8+ T cell numbers inc reased s ignificant ly in the VSV/anti-PD-L1 group compared t o is otype con trol (p=0.0119), and diff erent fr om the anti-PD-L1 only group (p=0.0287). CD4+ T cells were also significantl y inc reased in the VSV/anti-PD-L1 Ab group.
PMID 26712908
Title Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.